Last reviewed · How we verify

MSD Pharmaceuticals LLC — Portfolio Competitive Intelligence Brief

MSD Pharmaceuticals LLC pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Antiretroviral/Anti HIV Antiretroviral/Anti HIV marketed Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor) HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent) Infectious Disease / Virology
Golimumab Injection Golimumab Injection phase 3 TNF-α inhibitor (monoclonal antibody) TNF-α Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
  2. Biocad · 1 shared drug class
  3. Celltrion · 1 shared drug class
  4. Centocor, Inc. · 1 shared drug class
  5. Children's Memorial Health Institute, Poland · 1 shared drug class
  6. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 1 shared drug class
  7. Hanyang University Seoul Hospital · 1 shared drug class
  8. AbbVie (prior sponsor, Abbott) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MSD Pharmaceuticals LLC:

Cite this brief

Drug Landscape (2026). MSD Pharmaceuticals LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/msd-pharmaceuticals-llc. Accessed 2026-06-10.

Related